
Opinion|Videos|January 10, 2025
Assessing New Therapies for Retinal Diseases
Panelists discuss how aflibercept 8 mg demonstrates improved durability and maintenance of visual gains compared with 2-mg dosing, potentially reducing treatment burden while maintaining a similar safety profile.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- New Therapies:
- Aflibercept 8 mg
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Q&A: Evolving approaches to geographic atrophy management
2
Exploring Emerging Therapies in the Retinal Vascular Disease Pipeline
3
First patient treated in dose-expansion portion of SpliceBio's phase 1/2 ASTRA clinical trial
4
Rates of retinal layer thinning predict visual field progression in glaucoma
5















































